In line with this, inhibitors of the PI3K-Akt-mTOR pathway can be employed to enhance anthracycline sensitivity in ER positive breast cancers [10, 11] Whereas the introduction of Akt inhibitors in clinical trials has been slower than PI3K and mTOR inhibitors [12], the key position of Akt as a signal hub for important pro-tumorigenic pathways [6] makes such trials highly relevant. The gene discussed is MTOR; the disease is breast carcinoma.